Comparative Effectiveness Trials in Rheumatoid Arthritis

Rheumatology
Curriculum:
N/A
Credits:
1.5 AMA PRA Category 1 Credit(s)™
Launch Date:
January 28, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Rheumatologists, Rheumatology Nurses

Relevant Terms:

Rheumatoid Arthritis

Jeffrey R. Curtis MD, MS, MPH

Jeffrey R. Curtis MD, MS, MPH
Associate Professor of Medicine
Director, Arthritis Clinical Intervention Program (ACIP)
University of Alabama, Birmingham
Birmingham, AL

The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and other forms of inflammatory arthritis are among Dr. Curtis's research interests. He served on the Core Expert Panel for the ACR's 2008 and 2012 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He currently is the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources.
 
Dr. Curtis also studies risk factors for and outcomes of osteoporosis, particularly among men and non-Caucasians. He was a member of the ACR's task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He also served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.

Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), and the American Society of Bone and Mineral Research (ASBMR). He has authored more than 150 peer-reviewed articles and book chapters. He is on the editorial board for Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R).

Jeffrey D. Greenberg, MD, MPH

Jeffrey D. Greenberg, MD, MPH
Associate Director, Clinical Translational Sciences 
Departments of Medicine (Rheum Div) and Hospital for Joint Diseases 
NYU Langone Medical Center
New York, NY

Dr. Greenberg is a physician and epidemiologist with more than a decade of experience conducting research. He has been involved in the submission of more than 50 peer-reviewed manuscripts. His research focuses on health outcomes and pharmacoepidemiology in rheumatoid arthritis. 
 
Dr. Greenburg received his MD degree from McGill University and then went on to attain an MPH degree from UMDNJ. He previously served as the Associate Director of Clinical and Translational Sciences in a full-time faculty role at the NYU School of Medicine. He currently works as the Chief Scientific Officer at CORRONA (The Consortium of Rheumatology Researchers of North America).  

Joel M. Kremer, MD

Joel M. Kremer, MD
Pfaff Family Professor of Medicine
Albany Medical College
Director of Research, Center for Rheumatology
Albany, NY

Joel M. Kremer, MD, is a graduate of Temple University School of Medicine in 1974 where he was elected to the Alpha Omega Alpha honorary society. He completed both a residency in Internal Medicine and Fellowship in Rheumatology at The Albany Medical Center Hospital and The Albany Medical College. Dr. Kremer is Board Certified in Internal Medicine and Rheumatology. Between 1979 and 2000, Dr. Kremer served on the full time faculty of The Albany Medical College. He was appointed as Professor of Medicine in 1990 and became the Head of the Division of Rheumatology in 1992.
 
Dr. Kremer has been active in The American College of Rheumatology, serving as the President of the Northeast Region in 1992. Dr. Kremer has contributed over 120 original articles to the scientific literature. In addition, he has authored 18 book chapters and edited 3 texts on the rheumatic diseases. He serves on the Editorial Board of Arthritis Care and Research and The Journal of Rheumatology. He has been an invited lecturer at numerous academic institutions throughout this country and internationally. In 1977 he was awarded the Virginia Engalitcheff award of the Arthritis Foundation at a ceremony in Denver, Colorado for his work on methotrexate in patients with rheumatoid arthritis. The award is given to an individual who has "improved the quality of life of patients with arthritis over the past ten years". He is presently the Pfaff Family Professor of Medicine at the Albany Medical College and the Director of Research of The Center for Rheumatology in Albany, New York. He is also the president and founder of The Consortium of Rheumatology Researchers of North America (CORRONA), a national organization for furthering research in patients with rheumatic diseases.
1. Identify the primary similarities and differences between traditional drug research and comparative effectiveness research
2. Pinpoint the most clinically-important results from recent comparative effectiveness studies such as AMPLE, ADACTA, and TEAR
3. Apply safety and efficacy data from recent comparative effectiveness research in RA into clinical practice within the next 3 months

Instructions on How to Receive Credit
  • Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
  • Complete the entire activity, pre/post-test and evaluation.
  • After passing the post-test, print out your electronic CE certificate.
  • In order to successfully complete this activity learners must achieve a minimum of 65% on the post-test.
This activity is supported by an unrestricted educational grant from Genentech.

This activity is sponsored by the Institute for Continuing Healthcare Education

Release Date: January 28, 2014
Expiration Date: January 28, 2015

 
Accreditation Statements
Physicians
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Institute for Continuing Healthcare Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 
 
Disclosure
Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.

Faculty
 
Jeffrey R. Curtis, MD, MS, MPH
Associate Professor of Medicine
Director, Arthritis Clinical Intervention Program (ACIP)
Associate Director, Center for Education and Research
on Therapeutics of Musculoskeletal Disorders (CERTS)
University of Alabama, Birmingham
Birmingham, AL
 
Dr. Curtis, has disclosed the following relevant financial relationships that has occurred within the past 12 months: AbbVie, Amgen, Bristol-Myers Squibb, CORRONA, Cresendo, Genentech, Janssen, Roche and UCB/C, H.
 
Jeffrey D. Greenberg, MD, MPH
Associate Director, Clinical Translational Sciences
Departments of Medicine (Rheum Div) and Hospital for Joint Diseases
NYU Langone Medical Center
New York, NY
 
Dr. Greenberg, has disclosed the following relevant financial relationships that has occurred within the past 12 months: AstraZeneca, CORRONA, Pfizer/C; Pfizer/G; CORRONA/SS.
 
Joel M. Kremer, MD
Pfaff Family Professor of Medicine
Albany Medical College
Director of Research, Center for Rheumatology
Albany, NY
 
Dr. Kremer, has disclosed the following relevant financial relationships that has occurred within the past 12 months: AbbVie, Amgen, Bristol-Myers Squibb, Genentech, Lilly, Merck, Pfizer/A, C, G; AbbVie, Pfizer/PE, SB;CORRONA/SS.

Medical Writer
Kate Evans, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Peer Reviewer
Stanford Peng, MD
, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of this activity.

Activity Development and Management Team
Cathy Pagano, CCMEPScott Kober, CCMEPSandra Davidson; and Megan Small are employees of the Institute and have no relationships to disclose.

Off-label Product Disclosure
This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
 
For additional technical support, please send an email to msmall@iche.edu.
 
General Disclosure and Copyright Statement
The opinions expressed in this publication are those of the participating faculty and not those of the Institute for Continuing Healthcare Education (the Institute), Genentech, or any manufacturers of products mentioned herein.

This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.

Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.

Copyright 2014. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
 
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.